𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An assessment of the psychosocial needs of Huntington's disease families

✍ Scribed by Gregory J. Meissen; Eugene Maguin; Ann Woodruff


Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
548 KB
Volume
15
Category
Article
ISSN
0090-4392

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Interrater agreement in the assessment o
✍ Penelope Hogarth; Elise Kayson; Karl Kieburtz; Karen Marder; David Oakes; Diana πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 62 KB

## Abstract With prospects improving for experimental therapeutics aimed at postponing the onset of illness in preclinical carriers of the Huntington's disease (HD) gene, we assessed agreement among experienced clinicians with respect to the motor manifestations of HD, a relevant outcome measure fo

Assessment of coenzyme q10 tolerability
✍ Dr. A. Feigin; K. Kieburtz; P. Como; C. Hickey; D. Abwender; C. Zimmerman; K. St πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 273 KB

## Abstract We performed a 6‐month open‐label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD), Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS),

Assessment of simple movements reflects
✍ Carsten Saft; JΓΌrgen Andrich; Nina-Marie Meisel; Horst Przuntek; Thomas MΓΌller πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

Clinical rating, caudate atrophy, disturbed movement performance, neuropsychological testing, and age-related genetic disease load (CAG index) are tools that reflect impairment after onset of Huntington's disease (HD). Objectives were to compare scored HD symptoms, results of neuropsychological test

Clinical relevance of electrophysiologic
✍ Jean-Pascal Lefaucheur; Anne-Catherine Bachoud-Levi; Catherine Bourdet; Thierry πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 360 KB

Assessment programs recently designed to follow-up patients with Huntington's disease (HD) in therapeutic trials have not included electrophysiological testing in the list of mandatory examinations. This omission is likely due to the current lack of data establishing a clear correlation between the